BLRX is about to breakout. 6HR Chart Daily: Elliot Waves: Breakout should be imminent...
bad data today was release that cause the trend to reverse would be looking for the that 38.2% fib retrace to next area of supply, see if demand picks up there or it will fall further.
I read an article today that they are to provide the oils for CGC
GUESS ITS REALLY TIME THIS PENNY STOCKS GG TO RISE CHART LOOKS PRETTY GD PROMISING CO. VANGUARD DID ALSO ADD MILLIONS IN IT RECENTLY WITH MANY OTHERS HOPE YOU GUYS WILL EARN SOME TOO
$CELZ Remains unstoppable into the Mid May Bio Conference where they will be presenting, DD below in links.
$CELZ is currently on a clear and clean breakout in anticipation of the May 18th- 21st Presentation at the American Urological Association Convention in San Francisco. An 8K was released recently showing that shares were issued at .10 and as high as .30 levels The following link shows that the CEO has been buying on the way up as...
$CELZ broke above prior high on the last leg after a release of 8-Ks showing the clearing up of the rest of the company's debt and notes. Item 1.01 Entry into a Material Definitive Agreement Effective April 11, 2018, Creative Medical Technology Holdings, Inc. (the “ Company ”) amended promissory notes issued by it and by its operating subsidiary, Creative...
$BSPM . You should see the big picture... ;-) (For studying purpose only.)
An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China. Target: $31 (previous closing high), or long term hold Stop: $18 - $20
Very pleased to see new life being breathed into this stock based on the news today Article - finance.yahoo.com Fingers crossed for another big move upward next week. Gonna be a long weekend, have fun and stay safe
$IDXG Latest Insider Purchases, Institutional Ownerships and News: 2016-02-03 Glorikian Harry Director Acquired 127,696 2016-02-03 KEEGAN JOSEPH D Director Acquired 127,696 2016-02-03 STOVER JACK E Interim President and CEO Director Acquired 294,756 2016-02-03 SULLIVAN STEPHEN J Director Acquired 295,656 2017-06-23 SC 13G ARMISTICE CAPITAL, LLC Acquired...
Reposting as it didn't post properly the first time $DCTH Highlights for the first quarter of 2017 and the recent weeks include: First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter. CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT...
Huge breakout for ABBV closing the day above the double top formed from 2014/2015 highs between 70.70 and 71.60, both offering little resistance. RSI pushing into the high 80s shows good strong move up in my opinion, I won't be using RSI for short/sell/TP signal, rather buy more when it dips to over-sold territory on consolidation in the next few weeks... if that...
Nothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months: Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy”...
$CTRV announced today in addition to the 2017 Marcum MicroCap Conference 15-16 in New York, they will also be presenting at the San Diego Bio conference on June 19-22. Let's think about this hypothetically. If there was no news to present or bad news they wouldn't have more than one conference, I mean one conference would be more than enough to tell everything in...
$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to...
$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...